Lion Point Capital’s Arcutis Biotherapeutics ARQT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARQT
Lion Point Capital's ARQT Position: Q3 2026 in Review
Lion Point Capital held its Arcutis Biotherapeutics (ARQT) position steady in Q3 2026 at 5,250 shares worth $139K. The position accounts for 0.8% of the portfolio, ranked #31.
Lion Point Capital first reported a position in ARQT in Q3 2024 and has held it in 9 quarters since. The position peaked at $724K in Q1 2025. 294 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.
- Lion Point Capital held 5,250 shares of Arcutis Biotherapeutics worth $139K as of Q3 2026.
- Lion Point Capital left its Arcutis Biotherapeutics share count unchanged in Q3 2026.
- Arcutis Biotherapeutics made up 0.8% of Lion Point Capital's portfolio in Q3 2026, its #31 holding.
- Lion Point Capital first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 9 quarters since.
- Lion Point Capital's Arcutis Biotherapeutics position peaked at $724K in Q1 2025.
- 294 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.
Based on Lion Point Capital's 13F filing for Q3 2026, filed 16 Nov 2026.